Published 01 February 2018
Juniper Pharmaceuticals, a diversified healthcare company focused on women’s health, is exploring strategic alternatives in order to enhance shareholder value.
The company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives.
Juniper president and CEO Alicia Secor said: “Over the past year, we have made important investments into our core businesses, Juniper Pharma Services and Crinone, that supported strong double-digit revenue growth and established a strong financial foundation for Juniper.”
“Through this process, we are committed to working diligently to support continued growth of the business and to evaluating strategic options that enhance value for our shareholders.”
There can be no assurance that the exploration of strategic alternatives will result in a transaction. Any potential strategic alternative will be evaluated by the Board of Directors.
The Company does not intend to discuss developments with respect to the evaluation process unless a transaction is approved, or disclosure becomes appropriate.
Juniper Pharmaceuticals, Inc.’s core businesses include its CRINONE (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients.
Source: Company Press Release